THE CONCENTRATION OF INTERLEUKIN 6 AND TUMOR NECROSIS FACTOR ALPHA IN SALIVA AND BLOOD OF PATIENTS WITH INACTIVE MULTIPLE SCLEROSIS AND COEXISTING HASHIMOTO'S THYROIDITIS

Overview

Journal Acta Clin Croat

Specialty General Medicine

Date 2024 Mar 29

PMID 38549595

Authors

Ines Sisko Markos

Maja Franceschi

Valentina Vidranski

Pave Markos

Tomislav Jukic

Ana Frobe

Vanja Basic Kes

Affiliations

Soon will be listed here.

Abstract

The concentration of interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) in the blood is higher in patients with active multiple sclerosis (MS) compared to those with inactive disease. The concentration of IL-6 and TNF-α in the blood is higher in patients with Hashimoto's thyroiditis (HT) compared to those with a healthy thyroid. The aim of the study was to assess whether serum IL-6 and TNF-α levels correlated with saliva in patients with inactive MS and whether there was a difference in these groups of patients depending of thyroid status. We also examined the correlation of thyroid stimulating hormone (TSH) levels with thyroid status. The study included 54 patients in the inactive phase of MS. The level of cytokines in the blood was determined by chemiluminescence, and in saliva by ELISA. Blood and saliva IL-6 levels showed positive correlation, while blood and saliva TNF-α levels were not correlated. There was a significantly higher TSH level in patients with inactive MS with positive thyroid antibodies, without therapy, compared with those with negative antibodies.

References

Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G . Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc Natl Acad Sci U S A. 1995; 92(24):11294-8. PMC: 40618. DOI: 10.1073/pnas.92.24.11294. View

Wajant H, Pfizenmaier K, Scheurich P . Tumor necrosis factor signaling. Cell Death Differ. 2003; 10(1):45-65. DOI: 10.1038/sj.cdd.4401189. View

Zhang L, Yao C . The Physiological Role of Tumor Necrosis Factor in Human Immunity and Its Potential Implications in Spinal Manipulative Therapy: A Narrative Literature Review. J Chiropr Med. 2016; 15(3):190-6. PMC: 5021902. DOI: 10.1016/j.jcm.2016.04.016. View

Vladic A, Horvat G, Vukadin S, Sucic Z, Simaga S . Cerebrospinal fluid and serum protein levels of tumour necrosis factor-alpha (TNF-alpha) interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R gp80) in multiple sclerosis patients. Cytokine. 2002; 20(2):86-9. DOI: 10.1006/cyto.2002.1984. View

Domingues R, Fernandes G, Leite F, Tilbery C, Thomaz R, Silva G . The cerebrospinal fluid in multiple sclerosis: far beyond the bands. Einstein (Sao Paulo). 2017; 15(1):100-104. PMC: 5433316. DOI: 10.1590/S1679-45082017RW3706. View

Hanneman S, McCue D, Blog G . Validation of Salivary Interleukin-6 and Tumor Necrosis Factor-Alpha of Healthy Adult Volunteers by Enzyme Immunoassay. Nurs Res. 2016; 65(6):475-480. DOI: 10.1097/NNR.0000000000000186. View

Probert L . TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects. Neuroscience. 2015; 302:2-22. DOI: 10.1016/j.neuroscience.2015.06.038. View

Glass C, Saijo K, Winner B, Marchetto M, Gage F . Mechanisms underlying inflammation in neurodegeneration. Cell. 2010; 140(6):918-34. PMC: 2873093. DOI: 10.1016/j.cell.2010.02.016. View

Rasic I, Rebic V, Rasic A, Aksamija G, Radovic S . The Association of Simultaneous Increase in Interleukin-6, C Reactive Protein, and Matrix Metalloproteinase-9 Serum Levels with Increasing Stages of Colorectal Cancer. J Oncol. 2018; 2018:2830503. PMC: 6091449. DOI: 10.1155/2018/2830503. View

10.

Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H . Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol. 2007; 178(10):6092-9. DOI: 10.4049/jimmunol.178.10.6092. View

11.

Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T . Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 1999; 95(1):56-61. View

12.

Selmaj K, Raine C, Cannella B, Brosnan C . Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest. 1991; 87(3):949-54. PMC: 329886. DOI: 10.1172/JCI115102. View

13.

Nielsen C, Brix T, Leslie R, Hegedus L . A role for autoantibodies in enhancement of pro-inflammatory cytokine responses to a self-antigen, thyroid peroxidase. Clin Immunol. 2009; 133(2):218-27. DOI: 10.1016/j.clim.2009.07.014. View

14.

Tunbridge W, Evered D, Hall R, Appleton D, Brewis M, Clark F . The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf). 1977; 7(6):481-93. DOI: 10.1111/j.1365-2265.1977.tb01340.x. View

15.

Gijbels K, Van Damme J, Proost P, Put W, Carton H, Billiau A . Interleukin 6 production in the central nervous system during experimental autoimmune encephalomyelitis. Eur J Immunol. 1990; 20(1):233-5. DOI: 10.1002/eji.1830200134. View

16.

Ji A, Liu Z, Chen W, Huang W . The clinical significance of level changes of hs-CRP, IL-10 and TNF for patients with MS during active and relieving period. Eur Rev Med Pharmacol Sci. 2016; 20(20):4274-4276. View

17.

Rothaug M, Becker-Pauly C, Rose-John S . The role of interleukin-6 signaling in nervous tissue. Biochim Biophys Acta. 2016; 1863(6 Pt A):1218-27. DOI: 10.1016/j.bbamcr.2016.03.018. View

18.

Marchiori R, Pereira L, Naujorks A, Rovaris D, Meinerz D, Duarte M . Improvement of blood inflammatory marker levels in patients with hypothyroidism under levothyroxine treatment. BMC Endocr Disord. 2015; 15:32. PMC: 4476077. DOI: 10.1186/s12902-015-0032-3. View